Rezpegaldesleukin Receives Fast Track Designation for Moderate to Severe AD
Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.
Related Articles
Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): an International, Multicentre, Randomised, Placebo-Controlled Trial
Bruce Strober, MD, PhD, introduces an upcoming series highlighting a clinical trial focused on the efficacy and safety of subcutaneous spesolimab for the prevention of…
Long-Term Exposure to PM10 and PM2.5 May Reduce the Risk of Developing Melanoma
High concentrations of particulate matter can potentially lessen the exposure to UV radiation.
Kicking Off a New Year With Conferences, Special Features, and Expert Insights
Start the new year with a look at top dermatology conferences, expert insights, and the latest research on pigmentary disorders, psoriasis, and antiaging treatments.
Combination Therapy of LED Light and Chromophore Gel Successfully Treats Acne
Patients saw improvement in hydration, sebum, erythema, and scarring after just 3 treatment sessions.
Vitiligo Treatment Breakthrough: Bacterial Therapy May Restore Pigmentation
A microbial compound slows vitiligo in mice, paving the way for new treatment options beyond existing therapies.
Initiating and Navigating the Buy-and-Bill Process
Biologic coordinators play a key role in managing insurance approvals and ensuring coverage details are confirmed quickly, often within 48 hours.
Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis
This cohort study explores whether systemic inflammation is a mediator of the association between psoriasis skin disease severity and cardiovascular disease.
Top 5 Articles of the Week: February 2-7
Explore the top headlines of the week including Allergan Aesthetics’ new AA Signature program, the launch of EltaMD’s new UV Skin Recovery broad spectrum SPF…
More early career researchers are stepping up to peer review
Younger researchers are taking on the challenges of peer review — and reaping some unexpected benefits
